Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Keytruda, approved for several types of cancer ... Both the products are witnessing a strong launch. Merck has other promising candidates in its late-stage pipeline, such as MK-0616, an oral ...

The health sector faces challenges as Novo Nordisk's sales projections dim, Johnson & Johnson's unit faces hefty fines, and ...

Healthcare & Pharmaceuticalscategory· March 28, 2025 Merck plans to launch US subcutaneous version of Keytruda on October 1 Merck & Co said on Thursday that it plans to launch a subcutaneously ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Despite the broader market downturn, 10 individual stocks showed a strong performance during the trading session, with three ...

Merck (NYSE:MRK) experienced a 13% increase in its stock price over the last month, aided by several significant developments. The company's upcoming presentations at the American College of ...